Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated over a 12-week double-blind period with extensions up to one year. The trial design included a randomized withdrawal phase, allowing researchers to assess both treatment benefit and what happens when the medication is stopped. Results from this rigorous, placebo-controlled study contribute direct clinical evidence on whether a standardized cannabis extract can safely and effectively address a condition that affects hundreds of millions of people and remains poorly served by existing medications.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a significant clinical gap by evaluating a full-spectrum cannabis extract for chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options have demonstrated limited efficacy and substantial adverse effect profiles. The large sample size (n=820) and rigorous double-blind design provide level 1 evidence necessary to establish whether cannabinoid-based therapy represents a viable alternative to conventional analgesics and opioids for CLBP management. If efficacious and well-tolerated, VER-01 could expand the therapeutic armamentarium for a condition with profound public health burden and limited safe treatment options.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial adds meaningful data to the limited evidence base for full-spectrum cannabis in chronic low back pain, a condition where current pharmacologic options remain suboptimal. The relatively large sample size and rigorous design are commendable, though clinicians should note that the abstract’s truncation prevents assessment of the actual efficacy outcomes, safety profile, and comparison to established treatments or effect sizes. Key considerations for practice include the heterogeneity of CLBP itself, potential individual variation in cannabinoid responsiveness, drug interactions with concurrent medications, and the distinction between short-term efficacy (phase A) and longer-term tolerability (open-label extension). Before incorporating VER-01 into practice, providers will need to review the complete results to understand whether effect sizes justify use relative to physical therapy, NSAIDs, or other evidence-based approaches, and to identify which patient subgroups may benefit most. In the interim, this trial reinforces that cannabis-based medicines warrant continued rigorous investigation for pain
| |